Prolotherapy, Joint Sclerotherapy, and Ligamentous Injections with Sclerosing Agents

Prolotherapy, joint sclerotherapy, and ligamentous injections using sclerosing agents are explicitly non-covered because their medical effectiveness has not been established. Reimbursement is denied on the basis that these modalities are not reasonable and necessary per §1862(a)(1) of the Social Security Act.

"Prolotherapy, joint sclerotherapy, and ligamentous injections with sclerosing agents are not covered because their medical effectiveness has not been verified; reimbursement is denied as not reason..."

Sign up to see full coverage criteria, indications, and limitations.